Core Viewpoint - Bon Natural Life Limited has announced a share repurchase program allowing the company to buy back up to $1.0 million of its Class A ordinary shares, indicating confidence in its financial position and commitment to shareholder value [1]. Group 1: Share Repurchase Program - The company is authorized to repurchase shares in the open market, with the timing and number of shares depending on various factors such as price, market conditions, and corporate liquidity requirements [2]. - The share repurchase program is flexible and does not obligate the company to purchase a specific number of shares, allowing for potential suspension, modification, or discontinuation at any time [2]. Group 2: Appointment of Agent - Bon Natural Life Limited has appointed TradeUp Securities as its exclusive agent to facilitate the purchase of securities under the terms of a Purchase Plan Agreement [3]. Group 3: Company Overview - Bon Natural Life Limited is a Cayman Islands company operating in the natural, health, and personal care industries, emphasizing its role as a leading bio-ingredient solution provider [4].

Core Viewpoint - Bon Natural Life Limited has entered into a 36-month exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its patented postbiotic hypoglycemic ingredients, aiming to penetrate the global blood sugar health market with a contract value of 32 million US dollars [1]. Company Summary - Bon Natural Life Limited is a leading provider of bio-ingredient solutions in the natural, health, and personal care industry, focusing on innovative hypoglycemic solutions [1][5]. - The company holds a patent for a postbiotic hypoglycemic ingredient that effectively regulates blood sugar levels, particularly post-meal glucose spikes, and is characterized by its safety and ease of use [2]. Industry Summary - The postprandial blood glucose control market is valued at over 30 billion US dollars and is experiencing a compound annual growth rate of 7.5% [3]. - The company anticipates significant advancements in its hypoglycemic product line over the next 2-3 years, which is expected to drive sales growth and enhance investment value [4].